Hypophysitis following treatment with Ustekinumab: Radiological and pathological findings by Ramos-Levi, Ana M. et al.
March 2018 | Volume 9 | Article 831
Case RepoRt
published: 09 March 2018
doi: 10.3389/fendo.2018.00083
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Mônica Gadelha, 
Universidade Federal do Rio de 
Janeiro, Brazil
Reviewed by: 
Murat Aydin Sav, 
Acıbadem University, Turkey  
Jacqueline Trouillas, 
Claude Bernard University 
Lyon 1, France
*Correspondence:
Ana M. Ramos-Leví  
ana_ramoslevi@hotmail.com
Specialty section: 
This article was submitted 
to Pituitary Endocrinology, 








Núñez MA, Fraga J and Marazuela M 
(2018) Hypophysitis following 
Treatment with Ustekinumab: 
Radiological and 
Pathological Findings. 
Front. Endocrinol. 9:83. 
doi: 10.3389/fendo.2018.00083
Hypophysitis following treatment 
with Ustekinumab: Radiological and 
pathological Findings
Ana M. Ramos-Leví1*, Manuel Gargallo2, Ana Serrano-Somavilla1,  
Miguel A. Sampedro-Núñez1, Javier Fraga3 and Monica Marazuela1
1 Department of Endocrinology, Hospital Universitario de la Princesa, Instituto de Investigación Princesa, Universidad 
Autónoma de Madrid, Madrid, Spain, 2 Department of Endocrinology, Hospital Universitario Infanta Leonor, Madrid, Spain, 
3 Department Pathology, Hospital Universitario de la Princesa, Instituto de Investigación Princesa, Universidad Autónoma de 
Madrid, Madrid, Spain
Context: Ustekinumab is a human IgG1 monoclonal antibody that targets interleukin (IL)-12 
and IL-23, which may be useful in the treatment of autoimmune conditions such as psoriasis, 
psoriatic arthritis, and Crohn’s disease. Hypophysitis is an immune-derived inflammatory 
condition of the pituitary gland that may lead to pituitary dysfunction. With the increasing 
use of immunotherapy, it is possible that this and other new immune-related adverse events 
(IRAEs) arise, although the mechanisms involved are still incompletely defined.
Case description: A 35-year-old male, with a previous history of severe plaque- 
psoriasis who had started treatment with ustekinumab 4 months before, complained 
of progressive and persistent headache. Brain magnetic resonance imaging (MRI) was 
unremarkable. One year later, a new MRI was performed due to headache persistence, 
which revealed a homogenous and diffuse pituitary enlargement, with suprasellar 
extension and optic chiasm involvement, blurring of the pituitary stalk, absence of clear 
differentiation between the anterior and posterior lobes, and no signs of hemorrhage 
or adenomas. Endocrine evaluation was consistent with panhypopituitarism. Work-up 
of infiltrative and infectious diseases was negative. Follow-up MRI revealed an increase 
in the pituitary enlargement and transsphenoidal surgery was performed. Pathological 
findings revealed an intense fibrosis and a chronic inflammatory infiltrate, but no evidence 
of adenoma, granuloma, or acid fast bacilli. Immunohistochemical staining showed a 
combined T-cell (CD3+, CD4+) and B-cell (CD19+, CD20+) phenotype.
Conclusion: We suggest a novel IRAE of ustekinumab, with full radiological and 
immunopathological iconography, which may be mediated by the complex interaction 
between different immunological processes.
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BaCKGRoUND
Ustekinumab is a human IgG1 monoclonal antibody that targets interleukin (IL)-12 and IL-23. 
These two pro-inflammatory cytokines participate in immune functions, including the stimulation 
of natural killer cells and the differentiation of CD4+ T cells toward the T helper 1 phenotype (an 
action of IL-12), and the T helper 17 (Th17) pathway (an action of IL-23). Inhibiting their bioactivity 
may be useful in the treatment of autoimmune conditions such as psoriasis, psoriatic arthritis, and 
Crohn’s disease (1, 2).
FiGURe 1 | Brain magnetic resonance imaging (MRI) sections. Brain MRI, 
showing a homogenous and diffuse pituitary enlargement of up to 1.1 cm, 
which extended to the suprasellar region and contacted the optic chiasm, 
blurring of the pituitary stalk, absence of clear differentiation between the 
anterior and posterior lobes, and no signs of hemorrhage or adenomas.  
(a) Frontal T1-weighted after gadolinium; (B) frontal T2-weighted; and  
(C) sagittal T1-weighted after gadolinium.
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Hypophysitis is an immune-derived inflammatory condition of 
the pituitary gland that may lead to pituitary dysfunction. With the 
increasing use of immunotherapy, it is possible that this and other 
new immune-related adverse events (IRAEs) will continue to arise.
We here describe the case of a patient who developed hypo-
physitis following ustekinumab treatment for psoriasis. We sug-
gest potential mechanisms involved in its pathogenesis.
Case RepoRt
A 35-year-old male, with a previous history of severe plaque-
psoriasis who had started treatment with ustekinumab 4 months 
before, complained of progressive and persistent headache, which 
was refractory to non-steroidal anti-inflammatory drugs. Brain 
magnetic resonance imaging (MRI) was unremarkable. One year 
later, a new MRI was performed due to headache persistence, 
which revealed a homogenous and diffuse pituitary enlargement 
of up to 1.1 cm, which extended to the suprasellar region and con-
tacted the optic quiasm, blurring of the pituitary stalk, absence 
of clear differentiation between the anterior and posterior lobes, 
and no signs of hemorrhage or adenomas (Figure  1). Visual 
fields were normal. The patient acknowledged absence of signs 
or symptoms suggestive of pituitary dysfunction, except for mild 
libido decrease and erection difficulties. Physical examination 
revealed multiple psoriatic plaques, with no other remarkable fea-
tures. Laboratory work-up was consistent with hypogonadotropic 
hypogonadism, central hypothyroidism, central hypoadrenalism, 
and GH deficiency, but normality in the rest of the biochemical 
parameters evaluated (ions, proteins, lipid, renal, and hepatic 
profiles). Cerebrospinal fluid and work-up of infiltrative and 
infectious diseases, including sarcoidosis and tuberculosis, were 
negative. Follow-up MRI performed 6 months later revealed an 
increase in the pituitary enlargement to up to 1.7 cm. Because 
etiology of the mass was still unclear, the patient underwent 
transsphenoidal surgery of the sellar mass, with the purposes of 
both debulking and obtaining samples for biopsy.
Pathological findings revealed and intense fibrosis and a chronic 
inflammatory infiltrate of the pituitary gland with a high propor-
tion of lymphocytes and some plasmatic cells, but no evidence of 
adenoma, granuloma, or acid fast bacilli. Immunohistochemistry 
pointed to a combined T-cell (CD3+, CD4+, CD8+) and B-cell 
(CD19+, CD20+) phenotype. Additional immune analysis 
showed positivity for FOXP3, PD1, and IL-17, and negativity for 
IgG4 and S-100 protein (Figure 2).
Ustekinumab was withdrawn, with subsequent improvement 
of headaches. Laboratory work-up after surgery revealed persis-
tent panhypopituitarism, so hormonal replacement therapy was 
maintained. No other autoimmune disorders were evidenced in 
the clinical or analytical follow-up evaluation.
DisCUssioN
The use of ustekinumab for the treatment of psoriasis has progres-
sively increased in recent years. Common side-effects include 
mild gastro-intestinal disturbance, dizziness, depression, cold 
symptoms, and artro-myalgias. More severe effects include 
allergic hyper-sensibility and opportunistic infections such as 
FiGURe 2 | Pituitary gland serial sections from a representative area of the patient’s pituitary biopsy. Pituitary gland serial sections from a representative area of  
the patient’s pituitary biopsy, showing the most relevant immune-histopathological findings. Note the germinal center consisting of CD20+ B cells and peripheral 
CD3+ T cells (classified as T lymphocytes). Both CD4+ (helper) and CD8+ (cytotoxic) lymphocytes were found, as well as abundant macrophages (CD68+). 
T-regulatory cells were present in germinal centers and in the periphery (Foxp3+ and PD1+). Interleukin (IL)-17 staining was found not only in infiltrating lymphocytes 
but also in cells of pituitary origin in both hypophysitis and normal pituitary (data not shown). (a) Staining by hematoxylin–eosin; (B) synaptophysin; (C) CD20 (note 
how CD20+ cells form an aggregate, resembling a lymphoid follicle); (D) CD3; (e) CD4; (F) CD8; (G) CD68; (H) IL-17; (i) FOXp3; (J) PD1; (K) GH; and (L) prolactin. 
Sections (a–H) are shown as 10× and sections (i–L) as 20×.
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tuberculosis. However, although there is a potential risk of deve-
loping other IRAEs, this has been less explored (1).
Recently developed immunotherapeutic agents, which act 
as immune checkpoint inhibitors by releasing constraints on 
immune cells to promote antitumor activity, have generated 
promising results; specifically, the IgG1 monoclonal antibody 
Ipilimumab, which binds and inhibits cytotoxic T-lymphocyte 
antigen-4, or the IgG4 monoclonal antibodies Nivolumab and 
Pembrolizumab, which bind PD1. However, the immune- 
mediated antitumor effect frequently entails the development of 
other endocrine IRAEs, including hypophysitis, hypothyroidism, 
and adrenal insufficiency, especially in the case of Ipilimumab 
(3, 4). The reasons for these findings are still not fully understood 
but may concern modifications in the self-reactive effector T-cell 
repertoire and a further release of pituitary self-antigens, once 
pituitary inflammation and damage initiates, leading to the 
generation of more pituitary-reactive T-cells (4).
In this case report, hypophysitis possibly developed after treat-
ment with ustekinumab, another monoclonal antibody. IgG4-
mediated hypophysitis was reasonably ruled, given the negative 
pituitary IgG4 reactivity by immunohistochemistry, the absence 
of characteristic histopathologic findings, and the absence of any 
other clinical sign or symptom of IgG4-related disease at another 
site (5). Also, other causes of hypophysitis, such as histiocytosis, 
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sarcoidosis, or tuberculosis, were reasonably ruled out with 
further clinical and laboratory work-up. It is true that a potential 
association between psoriasis and hypophysitis has been vaguely 
suggested (6), and lymphocytic and granulomatous hypophysitis 
have been anecdotally described in the setting of a past medical 
history of psoriasis, but with no clearly documented relation-
ship (7, 8). However, in our patient, the absence of a correlation 
between the clinical course of both entities, the stability of skin 
plaques since the introduction of ustekinumab, the absence of any 
other autoimmune condition which could further be related to 
the potential development of hypophysitis, and the immunohis-
tochemical pattern observed may reasonably exclude the role of 
psoriasis in the development of this patient’s hypophysitis.
We suggest for the first time a case of a possible ustekinumab-
induced hypophysitis. In addition, apart from the biochemical 
work-up and radiological images, we provide novel immune-
histopathological findings. We observed a predominance of 
T-cells (CD3+, CD4+), which is characteristic of lymphocytic 
hypophysitis (9), and no granulomas. Specifically, the positive 
phenotypic expression for FOXP3 and PD1 suggests the pres-
ence of T-regulatory cells (Tregs). Although finding Tregs in 
hypophysitis may seem paradoxical, it could be hypothesized that 
treatment with ustekinumab could originate aberrant Tregs and 
entail an imbalance in the lymphocytic profile (9).
On the other hand, IL-17 expression, which is characteristic 
of Th17 cells, was present in both infiltrating lymphocytes and 
also in pituitary cells in a similar grade as in normal pituitary 
tissue. Finding IL-17 expression in a similar grade in both infil-
trating lymphocytes and normal pituitary cells could be due to 
the development of hypophysitis itself. In fact, T  lymphocytes 
undergo activation in the pituitary gland and produce increased 
levels of ILs, including IL-17, perpetuating the alteration. Normal 
pituitary cells do not usually express IL-17, in contrast to infiltrat-
ing lymphocytes and pituitary cells in the setting of hypophysitis, 
which do so. Moreover, the plasticity of Th cells and the existence 
of at least two subsets of Th17 lymphocytes, pathogenic or pro-
inflammatory, and non-pathogenic subsets, has been recently 
described (10) and can be identified by multiparametric flow 
cytometry, with analysis of the expression of the chemokine 
receptor CXCR3 (CD183), the P-glycoprotein 1 or multidrug 
resistance protein 1 (MDR1 or CD243), the differentiation mol-
ecule CD161, and the presence of IL-17 and IFN-γ. Moreover, 
IL-23 has been described to have a critical role on the differentia-
tion of pathogenic Th17 cells (11). By contrast, non-pathogenic 
Th17 cells could participate in the regulation of the inflammatory 
phenomenon (12, 13). In this regard, it has been suggested that 
non-pathogenic Th17  cells can differentiate into Treg lympho-
cytes, contributing to the downregulation of autoimmunity and 
chronic inflammatory conditions (14). In view of these findings, 
we can suggest that if IL-23 levels are altered due to ustekinumab, 
the balance between Th17 pathogenic and non-pathogenic cells 
may also be altered, resulting, in an aberrant lymphocytic infiltra-
tion, meaning that hypophysitis may consequently develop and 
perpetuate. In this way, ustekinumab-induced hypophysitis could 
represent various the lymphocytic-mediated model.
In conclusion, we suggest a novel IRAE of ustekinumab, which 
may be mediated by the complex interaction between cytokines, 
Treg and different Th subsets, and we provide full radiological 
and immunopathological iconography. The presence of a pre-
vious history of psoriasis, which is an autoimmune disease, may 
disguise a full comprehension of the mechanisms involved, given 
the potential combination of concomitant immune alterations. 
Further tissue and peripheral blood evaluation, also in the setting 
of other immune checkpoint inhibitors, may help understand the 
broad spectrum of hypophysitis, and evaluate the possible differ-
ent T-cell profile observed.
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